CAJ | 학술논문

目的评价自膨式裸支架(LifeStent(R))治疗股腘动脉狭窄闭塞性病变的近中期疗效及安全性.方法回顾性分析上海交通大学医学院附属第九人民医院2012年1月至2013年4月使用LifeStent(R)自膨式支架植入治疗67例股腘段动脉粥样硬化闭塞症(arteriosclerosis obliterans,ASO)患者(68例患肢),平均年龄(72±10)岁,其中严重肢体缺血19个(27.9％)患肢,术前踝肱指数(ankle brachial index,ABI)为0.44±0.18,病变平均长度(128±73) mm,分析参数主要为靶病变血运重建率(target lesion revascularization,TLR)、通畅率,保肢率、并发症发生率.结果术后复查ABI平均为(0.82 ±0.18),与术前比较差异有统计学意义(P＜0.01).术后平均随访(7±4)个月,失访7例.6个月及12个月免于TLR率分别为94.4％±3.1％、83.5％±6.5％,一期通畅率分别为90.7％±3.9％、73.3％±7.7％,二期通畅率分别为98.1％±1.8％、90.3％±5.6％.12个月保肢率为94.1％±4.4％.围手术期并发症8例(11.8％),无手术相关死亡及严重并发症.结论第2代自膨式支架治疗股腘动脉狭窄闭塞性病变近中期疗效满意.
목적 평개자팽식라지가(LifeStent(R))치료고객동맥협착폐새성병변적근중기료효급안전성.방법 회고성분석상해교통대학의학원부속제구인민의원2012년1월지2013년4월사용LifeStent(R)자팽식지가식입치료67례고객단동맥죽양경화폐새증(arteriosclerosis obliterans,ASO)환자(68례환지),평균년령(72±10)세,기중엄중지체결혈19개(27.9％)환지,술전과굉지수(ankle brachial index,ABI)위0.44±0.18,병변평균장도(128±73) mm,분석삼수주요위파병변혈운중건솔(target lesion revascularization,TLR)、통창솔,보지솔、병발증발생솔.결과 술후복사ABI평균위(0.82 ±0.18),여술전비교차이유통계학의의(P＜0.01).술후평균수방(7±4)개월,실방7례.6개월급12개월면우TLR솔분별위94.4％±3.1％、83.5％±6.5％,일기통창솔분별위90.7％±3.9％、73.3％±7.7％,이기통창솔분별위98.1％±1.8％、90.3％±5.6％.12개월보지솔위94.1％±4.4％.위수술기병발증8례(11.8％),무수술상관사망급엄중병발증.결론 제2대자팽식지가치료고객동맥협착폐새성병변근중기료효만의.
Objective To evaluate the up to mid term safety and efficacy of nitinol self-expanding stent (LifeStent (R)) implantation for femoropopliteal lesions.Methods In this study,67 patients (68 limbs) with de novo femoropopliteal lesions were treated by implanting a nitinol self-expanding stent (LifeStent,Bard Inc) from January 2012 through April 2013.Mean age was (72 ± 10) years,including critical limb ischemia in 19 limbs (27.9％),ankle brachial index (ABI) was 0.44 ±0.18 on baseline,the mean lesion length was (128 ± 73) mm.The endpoints was target lesion revascularization (TLR),patency rate,and limb salvage.Post-operative ABI,and complications.Results Post-operative ABI was (0.82 ± 0.18),significantly increased after operations (P ＜ 0.01).Mean follow-up time was (7 ± 4) months,with 7 patients lost to follow-up.Freedom from TLR,primary patency rate and secondary patency rate at 6 and 12 months were 94.4％ ±3.1％ and 83.5％ ±6.5％,90.7％ ±3.9％ and 73.3％ ±7.7％,98.1％ ± 1.8％ and 90.3％ ± 5.6％,respectively.Limb salvage rate at 12 months was 94.1％ ± 4.4％.Complications occurred in 8 limbs.There was no severe complications and inhospital mortality.Conclusions Nitinol self-expanding stent implantation for femoropopliteal lesions appears to be safe and efficient,based on its satisfactory clinical outcomes during a short-to mid-term follow up.